vcvibes

Tcg Crossover Management, LLC

Emerging manager

SEC-registered investment adviser.

HQ
CA

TCG Crossover is an investment firm focused on innovative biotech companies. It backs visionary entrepreneurs who use recent scientific breakthroughs to develop transformative medicines. Dandan Dong is Managing Partner. Portfolio companies named in the facts include Vor Bio, Century Therapeutics, Ollin Biosciences, Beacon Therapeutics, Pheon Therapeutics, Upstream Bio, and Arbor Biotechnologies.

01 · Says / Does

TagSaysDoes
StagesPre-seed, Seed, Series A, Series B, GrowthNot enough dated deals
SectorsBiotechNot enough dated deals
RegionsGlobalNot enough dated deals

Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.

02 · Fund history

FundYearSizeStatus
TCG Crossover Fund III, L.P.

TCG Crossover invests in innovative biotech companies and visionary entrepreneurs leveraging recent scientific breakthroughs to develop transformative medicines. It supports private and public companies and provides capital at any stage of a company's lifecycle. Inferred from the firm's website

approx. 2025$1200M (Form D)Raising
TCG Crossover Fund II, L.P.

TCG Crossover invests in innovative biotech companies and visionary entrepreneurs leveraging recent scientific breakthroughs to develop transformative medicines. It supports private and public companies and provides capital at any stage of a company's lifecycle. Inferred from the firm's website

approx. 2023$900M (Form D)Open, writing first checks
TCG Crossover Fund I, L.P.2021$800M (Form D)Follow-ons only

03 · People across funds

04 · Recent deals

No dated deals found yet.

05 · Latest from the firm

No news from the firm's website yet.

06 · Sources

  1. http://www.tcgcrossover.com
  2. https://tcgcrossover.com/contact/
  3. https://tcgcrossover.com/news/
  4. https://tcgcrossover.com/about-us/
  5. https://tcgcrossover.com/our-team/

Fund dates and sizes are from SEC Form D filings.

Last verified: Oct 28, 2026